Pritelivir demonstrated superior lesion healing with extended treatment compared to investigator's choice for refractory herpes simplex virus infection in immunocompromised patients in the PRIOH-1 phase III trial (ESCMID Global 2026) - Feb 4, 2026 - Abstract #E0203; Pres time: Apr 18, 2026; 02:51 PM - 02:57 PM; Location: Arena 1; No abstract available
Clinical • P3 data • Herpes Simplex • Infectious Disease
|
|
R. Chemaly; J.M. Molina; K. Workowski; R. Avery; Y.J. Lee; K. Peggs; D. Neofytos; M. Yong; J. Sasadeusz; R. Maves; B. Gaborit; D. Teschner; A. Perez-Rios; A. Birkmann; C. Wat; D.C. Herath; A. Marini; B. Surujbally; M. Sumner; A. Wald; G.A. Papanicolaou
|